Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

Trial Profile

Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Registrational
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 27 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Mar 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
    • 06 Dec 2016 Planned End Date changed from 1 Oct 2020 to 1 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top